Recursion and exscientia, two leaders in the ai drug discovery space, have officially combined to advance the industrialization of drug discovery

Salt lake city, nov. 20, 2024 (globe newswire) -- the business combination of two ai-powered drug discovery and development companies, recursion (nasdaq: rxrx) and exscientia has been completed, with exscientia becoming a wholly owned subsidiary of recursion creating a vertically-integrated and technology-enabled drug discovery platform. exscientia adss (nasdaq: exai) ceased trading and will be delisted from nasdaq.
EXAI Ratings Summary
EXAI Quant Ranking